201 related articles for article (PubMed ID: 11733371)
21. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
Giasson BI; Duda JE; Quinn SM; Zhang B; Trojanowski JQ; Lee VM
Neuron; 2002 May; 34(4):521-33. PubMed ID: 12062037
[TBL] [Abstract][Full Text] [Related]
22. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
Miao Y; Meng H
Cell Commun Signal; 2024 Jan; 22(1):31. PubMed ID: 38216911
[TBL] [Abstract][Full Text] [Related]
23. Fiber deprivation and microbiome-borne curli shift gut bacterial populations and accelerate disease in a mouse model of Parkinson's disease.
Schmit KJ; Garcia P; Sciortino A; Aho VTE; Pardo Rodriguez B; Thomas MH; Gérardy JJ; Bastero Acha I; Halder R; Cialini C; Heurtaux T; Ostahi I; Busi SB; Grandmougin L; Lowndes T; Singh Y; Martens EC; Mittelbronn M; Buttini M; Wilmes P
Cell Rep; 2023 Sep; 42(9):113071. PubMed ID: 37676767
[TBL] [Abstract][Full Text] [Related]
24. In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.
Price DL; Khan A; Angers R; Cardenas A; Prato MK; Bani M; Bonhaus DW; Citron M; Biere AL
NPJ Parkinsons Dis; 2023 Jul; 9(1):114. PubMed ID: 37460603
[TBL] [Abstract][Full Text] [Related]
25. miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy.
Xylaki M; Paiva I; Al-Azzani M; Gerhardt E; Jain G; Islam MR; Vasili E; Wassouf Z; Schulze-Hentrich JM; Fischer A; Outeiro TF
J Parkinsons Dis; 2023; 13(2):179-196. PubMed ID: 36744345
[TBL] [Abstract][Full Text] [Related]
26. Pre-clinical Studies Identifying Molecular Pathways of Neuroinflammation in Parkinson's Disease: A Systematic Review.
Fathi M; Vakili K; Yaghoobpoor S; Qadirifard MS; Kosari M; Naghsh N; Asgari Taei A; Klegeris A; Dehghani M; Bahrami A; Taheri H; Mohamadkhani A; Hajibeygi R; Rezaei Tavirani M; Sayehmiri F
Front Aging Neurosci; 2022; 14():855776. PubMed ID: 35912090
[TBL] [Abstract][Full Text] [Related]
27. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
Moors TE; Mona D; Luehe S; Duran-Pacheco G; Spycher L; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Dernick G; van de Berg WDJ; Britschgi M
Acta Neuropathol Commun; 2022 Jun; 10(1):82. PubMed ID: 35659116
[TBL] [Abstract][Full Text] [Related]
28. A brief history of brain iron accumulation in Parkinson disease and related disorders.
Foley PB; Hare DJ; Double KL
J Neural Transm (Vienna); 2022 Jun; 129(5-6):505-520. PubMed ID: 35534717
[TBL] [Abstract][Full Text] [Related]
29. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.
Cascella R; Bigi A; Cremades N; Cecchi C
Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787
[TBL] [Abstract][Full Text] [Related]
30. Retinal Degeneration: A Window to Understand the Origin and Progression of Parkinson's Disease?
Zhang Y; Zhang X; Yue Y; Tian T
Front Neurosci; 2021; 15():799526. PubMed ID: 35185448
[TBL] [Abstract][Full Text] [Related]
31. Chronic Exposure to Paraquat Induces Alpha-Synuclein Pathogenic Modifications in
Arsac JN; Sedru M; Dartiguelongue M; Vulin J; Davoust N; Baron T; Mollereau B
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769043
[TBL] [Abstract][Full Text] [Related]
32. DJ-1 Acts as a Scavenger of α-Synuclein Oligomers and Restores Monomeric Glycated α-Synuclein.
Atieh TB; Roth J; Yang X; Hoop CL; Baum J
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680099
[TBL] [Abstract][Full Text] [Related]
33. Advances of Mechanisms-Related Metabolomics in Parkinson's Disease.
Zhang Y; Li J; Zhang X; Song D; Tian T
Front Neurosci; 2021; 15():614251. PubMed ID: 33613180
[TBL] [Abstract][Full Text] [Related]
34. Reverse engineering Lewy bodies: how far have we come and how far can we go?
Fares MB; Jagannath S; Lashuel HA
Nat Rev Neurosci; 2021 Feb; 22(2):111-131. PubMed ID: 33432241
[TBL] [Abstract][Full Text] [Related]
35. Temperature is a key determinant of alpha- and beta-synuclein membrane interactions in neurons.
Ramalingam N; Dettmer U
J Biol Chem; 2021; 296():100271. PubMed ID: 33428933
[TBL] [Abstract][Full Text] [Related]
36. Hippocampal network hyperexcitability in young transgenic mice expressing human mutant alpha-synuclein.
Tweedy C; Kindred N; Curry J; Williams C; Taylor JP; Atkinson P; Randall F; Erskine D; Morris CM; Reeve AK; Clowry GJ; LeBeau FEN
Neurobiol Dis; 2021 Feb; 149():105226. PubMed ID: 33347975
[TBL] [Abstract][Full Text] [Related]
37.
Caputo A; Liang Y; Raabe TD; Lo A; Horvath M; Zhang B; Brown HJ; Stieber A; Luk KC
eNeuro; 2020; 7(4):. PubMed ID: 32788297
[TBL] [Abstract][Full Text] [Related]
38. Death-associated Protein Kinase 1 Phosphorylates α-Synuclein at Ser129 and Exacerbates Rotenone-induced Toxic Aggregation of α-Synuclein in Dopaminergic SH-SY5Y Cells.
Shin WH; Chung KC
Exp Neurobiol; 2020 Jun; 29(3):207-218. PubMed ID: 32624505
[TBL] [Abstract][Full Text] [Related]
39. Brain Hepcidin Suppresses Major Pathologies in Experimental Parkinsonism.
Liang T; Qian ZM; Mu MD; Yung WH; Ke Y
iScience; 2020 Jul; 23(7):101284. PubMed ID: 32623334
[TBL] [Abstract][Full Text] [Related]
40. Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk.
Kayed R; Dettmer U; Lesné SE
J Parkinsons Dis; 2020; 10(3):791-818. PubMed ID: 32508330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
